Bouygues Construction and Suez Group have both contributed to an $11.3m round that will fund the construction waste removal service's European expansion.

The immunotherapy developer, which is majority owned by BGI Group, has secured $17.8m in a GF Securities-led round that will fund clinical work on its lead product candidate.

The data centre technology developer will put the proceeds from the CUI-led round into its marketing and research and development activities.

BioLeaders is investing $10m in an as yet unnamed spinout from Weizmann Institute of Science working on a genetic drug for cancer.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The funding will be funnelled into an unnamed p53 suppressor-focused oncology Weizmann spinout and ultrasound guidance device maker On-Sight Medical.

Sherlock Biosciences will develop molecular diagnostics tools co-developed by researchers at Harvard University and Broad Institute, including Crispr inventor Feng Zhang.

Ease, the HR enrolment and benefits software provider formerly known as EaseCentral, took its total funding to almost $28m in a Propel Venture Partners-backed series B round.

Virgo Investment Group has invested $18m in the PAR-backed online fitness platform in the form of series C funding, bringing its overall equity financing to $41m.

The AI-powered energy management app provider has secured $12m in series A funding from investors including BKK.